S64315
Total Payments
$85,905
Transactions
25
Doctors
0
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $85,905 | 25 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $85,905 | 25 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia | Servier BioInnovation | $63,639 | 0 |
| Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia | INSTITUT DE RECHERCHES INTERNATIONALES SERVIER | $22,265 | 0 |
Top Doctors Receiving Payments for S64315
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $85,905 | 25 |
Ad
Manufacturing Companies
- Servier BioInnovation $63,639
- INSTITUT DE RECHERCHES INTERNATIONALES SERVIER $22,265
Product Information
- Type Drug
- Total Payments $85,905
- Total Doctors 0
- Transactions 25
About S64315
S64315 is a drug associated with $85,905 in payments to 0 healthcare providers, recorded across 25 transactions in the CMS Open Payments database. The primary manufacturer is Servier BioInnovation.
Payment data is available from 2024 to 2024. In 2024, $85,905 was paid across 25 transactions to 0 doctors.
The most common payment nature for S64315 is "Unspecified" ($85,905, 100.0% of total).
S64315 is associated with 2 research studies, including "Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia" ($63,639).